Welcome to ProGenaCell Restorative Medicine
ProGenaCell -- a global restorative healthcare provider -- has developed multiple biological products to treat a broad range of neurological and chronic related diseases.
ProGenaCell physicians are committed to effectively treating chronically ill patients – particularly neuronal conditions (e.g. Parkinson’s disease, autism spectrum disorder, stroke, traumatic brain injury, etc.), autoimmune disease (e.g. M.S. chronic fatigue, lupus, etc.), and joint-related pain.
ProGenaCell recently announced the release of its latest state-of-the-art healing procedure; a restorative therapy designed to treat a multitude of diseases (see links above). These treatments have been clinically shown to repair tissues damaged from aging, trauma, and more – through the identification, repair, and/or restoration of healthy new cells and tissues.
ProGenaCell affiliate clinics and hospitals have treated over 4,000 patients since the early 2000s.
ProGenaCell maintains full control over its entire manufacturing cycle, from testing and processing to delivery of products for clinical use. This oversight and integrative process ensure exceedingly high safety and quality levels for patients. In addition, ProGenaCell works closely with affiliate centers in modifying and advancing treatment protocols and patient care.
ProGenaCell Restorative Therapy
ProGenaCell products release a variety of trophic factors, growth factors, and cytokines known to enhance the restore brain process. Various treatments have been used by clinicians to limit brain cell damage and reduce its symptoms. Their unique differentiation, unlimited multiplication properties make them an idea in the application of restorative medicines. Our products differentiate into areas of the body in needing of repair, restoring damaged cells, and helping in resuming the function of the damaged organs under suitable conditions. Direct replacement of neuronal cells with functional connections is less likely given the complexity of neural networks and the short time frame in which improvement is seen. Multiple mechanisms may work in some cases contributing to overall functional improvement. In the acute to subacute phase after stroke, the intravenous route might be best as a neuroprotective or anti-inflammatory strategy. At later time intervals, intrathecal routes might be preferable to better reach ischemic areas and deliver trophic factors. In a chronic stroke, direct intracerebral injection is more preferable for delivery cells to brain areas surrounding infarction capable of enhancing recovery.
ProGenaCell Fresh vs Frozen Therapy
Freezing restorative fresh products causes progressive damage during each of its three development phases: 1) cooling 2) more cooling, and 3) thawing. In addition to metabolic imbalances, measurable changes occur in the organelle membrane (lipid domains). These structural characteristics (transitions) result in a change in membrane fluidity from an ideal liquid-crystalline state to a far less preferred solid gel state; yielding a "leaky" membranous state.
Moreover, a cascade of damaging events generally occurs, including:
- Activation/leakage of lysosomal lipoprotein.
- Activation of calcium-dependent phospholipases/release of free fatty acids.
- Activation of product death.
- Disruption of the cytoskeletal matrix.
- Generation of free radicals/oxidative stressors caused by freezing.
Neuronal and Mesenchymal Products
ProGenaCell administered select products for many neurological conditions, like Parkinson’s disease, Autism, cerebral palsy, spinal muscular atrophy, ataxia, optic nerve conditions, and traumatic brain injury – many non-neuronal derived conditions amenable to our products.Learn More